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Abstract [249 Words] 40 
 41 
 42 
Objective 43 
Unlike complete (R0) resection guidelines, current National Comprehensive Cancer 44 
Network (NCCN) adjuvant therapy guidelines after incomplete (R1/R2) resection of non-45 
small cell lung cancer (NSCLC) are based on low-level evidence. We attempted to 46 
validate them. 47 
 48 
Methods 49 
Patients with pathologic stage I-IIIA NSCLC from 2004-2011 in the National Cancer 50 
Data Base were stratified by margin status, NCCN-specified stage groupings and 51 
adjuvant therapy exposure (none, radiotherapy, chemotherapy or both). Five-year 52 
overall survival (OS) and hazard ratios, adjusted for patient and institutional 53 
characteristics, were compared. We used a parallel analysis of R0 resections to validate 54 
our methodology.  55 
 56 
Results  57 
We analyzed 3461 R1/R2, and 78,929 R0 resections. After R0 resection, the NCCN-58 
recommended option was associated with the best survival across all stage groups, 59 
supporting our analytic approach.  R1/R2 stage IA patients treated with radiation had a 60 
26% OS, compared to 58% with no treatment (p=0.003). In stage IB/IIA(N0) R1/R2 61 
patients, radiation was associated with a 25% OS compared to 47% with no treatment 62 
(p=0.025) and 62% with chemotherapy (p<0.007). Chemoradiation was not associated 63 
with a survival benefit in either group. Patients with IIA (N1)/IIB and IIIA had better 64 
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survival with chemotherapy or chemoradiation. No group had a survival benefit with 65 
radiation alone.  66 
 67 
Conclusions  68 
NCCN adjuvant therapy guidelines after complete resection, based on high-level 69 
evidence, are validated, but not guidelines for patients with incompletely resected early 70 
stage NSCLC, which are based on low-level evidence. Monomodality postoperative 71 
radiotherapy was not validated for any stage. Specific studies are needed to determine 72 
optimal management after incomplete resection. 73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
 87 
 88 
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 89 
Perspective Statement 90 
 91 
 92 
NCCN guidelines for post-operative chemotherapy and radiation after complete surgical 93 
resection for NSCLC, based on high-level evidence, are validated in this analysis. 94 
Current guidelines for post-operative therapy after incomplete resection of stage I-II 95 
NSCLC, which are based on lower-level evidence, are not supported by this analysis.   96 
 97 
Central Message 98 
 99 
NCCN guidelines for post-operative therapy after incomplete surgical resection in stage 100 
I-II patients should be prospectively evaluated. 101 
 102 
 103 
 104 
Abbreviations 
National Comprehensive Cancer Network  NCCN 
Postoperative radiotherapy  PORT 
Randomized clinical trials  RCTs 
Non-small-cell lung cancer  NSCLC 
National Cancer Database  NCDB 
Interquartile range IQR 
Overall survival  OS 
Hazard Ratio HR 
 105 
 106 
  107 
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Introduction 108 
Lung cancer accounts for approximately 27% of all annual US cancer deaths.1 Most 109 
long-term survivors are among the 29% of patients who have undergone curative-intent 110 
surgical resection.2,3 In high-risk patients, adjuvant chemotherapy 4-6 and/or 111 
postoperative radiotherapy (PORT) may improve survival.7  The quality of evidence for 112 
the benefit of these treatments varies by stage and margin status.7-10 113 
 114 
Randomized clinical trials (RCTs) and a pooled analysis have demonstrated the benefit 115 
of adjuvant chemotherapy in completely (R0) resected patients with T-category 2b or 116 
more advanced primary tumors, and those with nodal metastasis.4-6,11  A large meta-117 
analysis showed the harmfulness of PORT in R0-resected patients without mediastinal 118 
nodal metastasis12,13; a retrospective analysis of the US Surveillance, Epidemiology and 119 
End Results database and an unplanned retrospective analysis of a clinical trial suggest 120 
R0 patients with mediastinal nodal metastasis may benefit from PORT.7,10 121 
 122 
Unlike the situation after complete resection, there is no RCT evidence to guide 123 
adjuvant management for the 2-17% of non-small-cell lung cancer (NSCLC) resections 124 
with microscopic (R1) or macroscopic (R2) positive margins.14-16  However, recipients of 125 
incomplete resection are at significantly high risk for early death, irrespective of stage.16-126 
18
 Current National Comprehensive Cancer Network (NCCN) guideline 127 
recommendations for post-operative management of these patients are based on 128 
unverified expert opinion.19  Therefore, the guidelines need validation.  129 
 130 
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We evaluated the survival impact of four different adjuvant therapy options, after 131 
incomplete resection, in the National Cancer Database (NCDB) to determine which 132 
options seemed best for patients grouped into stage clusters as in the NCCN 133 
guidelines.19  134 
Methods 135 
Cohort selection. We used the NCDB, an oncology database sourced from Commission 136 
on Cancer-accredited facilities, which covers approximately 70% of newly diagnosed 137 
US cancer cases.20,21  We selected patients with surgically resected pathologic stage I-138 
IIIA NSCLC from 2004-2011 (International Classification of Disease for Oncology, 9th 139 
edition [ICD-9-CM] site codes C34.0 – C34.9), excluding patients with missing 140 
information on last date of contact, administration (or date of administration) of radiation 141 
or chemotherapy, facility or patient location. We also excluded patients with more than 142 
one surgical procedure, neoadjuvant radiation or chemotherapy, no (or unknown) nodal 143 
examination, adjuvant therapy more than 180 days past date of diagnosis, government 144 
insurance and death within 60 days of surgery.  145 
 146 
Objectives. The primary objective of this analysis was to compare stage-specific 147 
survival between post-operative therapy modalities in patients with incomplete surgical 148 
resection (R1/R2) who did not undergo re-resection.  We used a parallel analysis of R0 149 
patients to evaluate whether our data and methodology produced results congruent with 150 
existing high-level evidence for treatment of R0 patients. 151 
 152 
Adjuvant therapy options. We classified post-operative therapy modalities as 153 
chemotherapy, radiotherapy, chemoradiation, or no treatment.  Therapy administered 154 
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within six months after surgery, at any dose level, was included as post-operative 155 
therapy. The median time from surgery to onset of treatment, by modality, is reported in 156 
Supplemental Table I. For combined modality chemoradiation therapy, the second 157 
modality had to begin within 2 months of the end of the first. The time from surgery to 158 
initiation of adjuvant therapy was evaluated to verify that adjuvant modalities were not 159 
typically used for the purpose of salvage therapy in this cohort. 160 
 161 
NCCN stage groups and adjuvant therapy guidelines. NCCN recommendations for 162 
adjuvant therapy are based on pathologic stage, categorized into the following four 163 
groups: 1. Stage IA (T1ab, N0); 2. Stage IB (T2a, N0) and Stage IIA (T2b, N0); 3. Stage 164 
IIA (T1ab-T2a, N1) and Stage IIB (T3, N0; T2b N1); 4.  Stage IIIA (T1-3, N2; T3, N1).  165 
The NCCN-recommended non-surgical adjuvant therapy for group 1 is PORT; for group 166 
2, PORT with or without chemotherapy; for groups 3 and 4, chemoradiation (sequential 167 
or concurrent) for R1 and concurrent chemoradiation for R2.19  168 
 169 
Variables. Margin status was evaluated as negative (R0) or positive (R1, R2 or positive 170 
not otherwise specified), and in subsequent analyses R1 and R2 were evaluated 171 
individually.  Covariates (detailed in Table 1 and Supplemental Table I) in the analysis 172 
included patient demographic (age, sex, race, insurance status, income, rural/urban 173 
residence, census region), and clinical characteristics (number of comorbidities [0,1, or 174 
≥2], histology, tumor grade, tumor size, primary site, type of surgery), as well as 175 
institutional characteristics (facility type).  176 
 177 
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Statistical Analysis 178 
 179 
Overall survival (OS) times were taken from the date of surgery until the date of death 180 
or last follow-up.  Survival analyses were conducted to compare the four post-operative 181 
treatment modalities within each of the four stage groups.  OS was estimated using the 182 
Kaplan-Meier method and post-operative treatment groups were compared using the 183 
log-rank test. 184 
 185 
OS comparisons were also evaluated using univariate Cox proportional hazards models 186 
and multiple variable Cox proportional hazards models to adjust for covariates.  Model-187 
based hazard ratio estimates are reported with 95% confidence intervals.  For each 188 
model we present unadjusted hazard ratios and hazard ratios adjusted for demographic, 189 
clinical, surgical, and institutional characteristics.  The proportional hazards assumption 190 
was evaluated graphically, using log(-log) survival plots by treatment group. We used 191 
‘no adjuvant treatment’ as the reference adjuvant therapy option, since there is no 192 
clinical trial evidence to support adjuvant therapy after incomplete NSCLC resection. P-193 
values less than 0.05 were considered statistically significant with no adjustment for 194 
multiple comparison and all analyses were conducted in SAS Version 9.4 (Cary, NC). 22 195 
 196 
 197 
Sensitivity Analyses. We conducted multiple sensitivity analyses to address specific 198 
details of the analysis. First, the specific type of positive resection (R1 or R2) was 199 
unknown for some margin-positive patients.  We evaluated the sensitivity of our results 200 
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to margin-positivity of unknown type by conducting multiple analyses in which we 201 
grouped them as R1, R2, and eliminated them.   202 
 203 
Additional sensitivity analyses were conducted to evaluate if departures from 204 
proportional hazards or the large number of covariates adjusted for in each model could 205 
impact the observed results from primary analysis.  In these analyses, propensity-score 206 
adjusted models were used to control for demographic, clinical, surgical, and 207 
institutional characteristics with a propensity score, which was entered into the model as 208 
a covariate.23  209 
 210 
Finally, we evaluated the potential impact of departures from the proportional hazards 211 
assumption by re-evaluating the multiple variable Cox models after eliminating any 212 
exposure groups where the assumption was questionable. 213 
 214 
Results 215 
 216 
A total of 82,440 patients were eligible: 3461 (4%) with incomplete resection, the 217 
primary analysis group of interest (Figure 1), and 78,979 (96%) with R0 resection 218 
(Supplemental Figure I), used to validate our analytic approach.  The demographic and 219 
clinical characteristics of these patients, stratified by NCCN stage group (Table 1A [non-220 
R0] and Supplemental Table IIA [R0]) and adjuvant therapy exposure (Table 1B [non-221 
R0] and Supplemental Table IIB [R0]), are presented.   222 
 223 
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Early-stage patients with incomplete resection: NCCN groups 1 and 2. OS estimates 224 
were compared by treatment modality in margin-positive patients with stage IA (T1ab, 225 
N0) and stages IB/IIA (T2a, N0 and T2b, N0).  Margin-positive stage IA patients who 226 
received PORT alone had significantly lower OS compared to those with no treatment 227 
(5-Year OS: 26% vs. 58%, p-value=0.0030, Table 2, Figure 2A).  This result trended 228 
towards statistical significance in the fully adjusted model (aHR: 1.7, p-value=0.0551, 229 
Table II).  Similarly, for stage IB/IIA patients, the 5-year OS was 47% with no treatment, 230 
and 25% with PORT (p-value=0.0251; aHR 1.28, p-value=0.12) (Table 2, Figure 2B). 231 
 232 
We found no significant association between chemotherapy and survival in stage IA 233 
patients with positive margins.  However, survival was significantly higher in persons 234 
with stages IB-IIA who received post-operative chemotherapy compared to no treatment 235 
(5-Year OS: 62% vs. 47%, p-value=0.0065, Table 2, Fig 2B).  These results remained 236 
statistically significant in fully-adjusted models (aHR 0.58, p-value=0.0040, Table 2).  237 
Sensitivity analysis using propensity score-adjusted models (Supplemental Table III) 238 
and those that did not consider treatment groups where the proportional hazards 239 
assumption may be violated (Supplemental Table IV) provided consistent results. 240 
Survival with chemoradiation was not significantly different from no adjuvant treatment 241 
in group 1 or 2 patients (Table 2).  242 
 243 
Late-stage patients with incomplete resection: NCCN groups 3 and 4. In margin-positive 244 
NCCN group 3, patients with Stage IIA (T1ab-T2a, N1) or Stage IIB (T3, N0;T2b N1), 245 
those who received radiation had a similar survival experience to those who received no 246 
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treatment (5-Year OS: 26% vs. 27%, p-value= 0.59, Figure 2C, Table 2).  Recipients of 247 
chemotherapy or chemoradiation had superior survival (p-values<0.0010, Table 2, 248 
Figure 2C).  Results were similar in fully adjusted models, where the chemotherapy 249 
group had 0.72 times the hazard of death compared to no treatment (p-value=0.0041), 250 
and the chemoradiation group had 0.74 times the hazard of death (p-value=0.0083).   251 
 252 
Subsequent analysis found no substantial differences in survival in the chemoradiation 253 
group based on the order in which therapies were administered (Supplemental Table 254 
V).  When evaluated separately, patients receiving chemotherapy first and then 255 
radiation had 37% 5-Year OS compared to 36% for patients receiving radiation first and 256 
then chemotherapy and 38% for those receiving both concurrently (Supplemental Table 257 
V).   258 
 259 
Consistent with NCCN guidelines, margin-positive patients with stage IIA or stage IIB 260 
were further delineated based on the specific type of incomplete resection, R1, R2, or 261 
unknown (margin-positive, but type not specified).  Although potentially limited by 262 
smaller sample sizes, results were largely consistent with those observed for all margin-263 
positive patients combined (Supplemental Table VI ).   264 
 265 
In margin-positive NCCN group 4, patients with Stage IIIA (T1-3, N2; T3, N1), 5-year 266 
OS was similar between patients who received PORT (10%) and no treatment (12%, p-267 
value=0.52, Fig 2d).  However, compared with no treatment, patients with 268 
chemotherapy alone had higher 5-year OS (21% vs. 12%, p-value=0.0045), as did 269 
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those with chemoradiation (25%, p-value <0.0001).  Fully adjusted models confirmed 270 
these findings (Table 2). Specifically, the patients had a lower hazard of death in both 271 
the chemotherapy group (aHR=0.77, p-value= 0.0466) and the chemoradiation group 272 
(aHR 0.63, p-value <0.0001), compared to no treatment.  273 
 274 
Analysis of margin-positive patients with stage IIIA, after further stratification into R1 or 275 
R2 subsets, yielded similar results to the combined cohort (Supplemental Table VI).  276 
Similar to group 3 patients, we found no meaningful difference in survival in Stage IIIA 277 
patients based on the order that chemoradiation was received (Supplemental Table V). 278 
 279 
Validation analysis with margin-negative resections. We applied the same analysis to 280 
the R0 resection cohort in a parallel analysis.  Five-year OS, unadjusted proportional 281 
hazards models, and adjusted proportional hazards models in this cohort are presented 282 
in Table 3 and Supplemental Figure II.  We further delineated the stage IIIA margin-283 
negative survival analysis by pN-category (N0/N1 vs. N2) to match the NCCN 284 
guidelines subsets and evaluated their comparative OS based on adjuvant therapy 285 
exposure (Supplemental Table VII). The pattern of adjuvant therapy benefit in our 286 
analysis matched up with the evidence-based NCCN guidelines for R0 resection (Table 287 
4).  288 
 289 
Comparison with NCCN Recommendations  Results from margin-positive and margin-290 
negative analyses by stage groups are summarized qualitatively in Table 4, and are 291 
compared with the current NCCN recommendations.    292 
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 293 
Discussion 294 
 295 
We compared OS between post-operative adjuvant therapy modalities in patients with 296 
completely and incompletely resected NSCLC, to determine if current NCCN 297 
recommendations are supported by a robust nationally-representative dataset. Our 298 
primary interest was in the patients with incomplete resection, but we used the R0 299 
cohort to validate our methodology, and the suitability of the NCDB for this purpose. 300 
This analysis consistently corroborated NCCN guidelines backed by high-level clinical 301 
trial evidence, but did not support current recommendations in several scenarios after 302 
incomplete resection, where the available evidence is sparse. 303 
 304 
In patients with completely resected stage IA NSCLC, RCT have shown no benefit from 305 
adjuvant therapy.4,6 In stage IB-IIB, RCTs and a pooled analysis including the five 306 
largest studies, have shown an increase in overall and relapse-free survival with post-307 
operative Cisplatin-based chemotherapy compared to observation.4-6,11  Our analysis of 308 
the R0 cohort is consistent with this evidence.  Specifically, patients with completely 309 
resected stage IB-IIA NSCLC who received chemotherapy had results superior to all 310 
other treatment groups.  In patients with completely resected stage IIIA NSCLC, current 311 
evidence supports chemotherapy for those with N0 or N1, and chemotherapy or 312 
chemoradiation for those with N2, which is the current NCCN recommendation.19 The 313 
R0 cohort analysis supports the use of chemotherapy in N0 and N1 patients, and 314 
chemotherapy with or without radiation in patients with N2.  315 
 316 
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Incomplete resections occur relatively infrequently, and adjuvant therapy trials 317 
specifically exclude these patients.4-7,10,11,24  Therefore, there is no definitive evidence 318 
on the best choice of post-operative therapy in this situation.16-18  NCCN guidelines 319 
currently recommend PORT for group 1 (stage IA), PORT with or without chemotherapy 320 
for group 2 (stage IB and IIA), and chemoradiation for groups 3 (stage IIA with N1 and 321 
IIB) and 4 (T3N1 and T1-3,N2).19 Our analysis supports observation for group 1, 322 
chemotherapy only for group 2, chemotherapy with or without radiation for group 3, and 323 
chemoradiation therapy for group 4. This analysis supports the NC N 324 
recommendations for groups 3 and 4, but suggests that the current recommendations 325 
may be harmful to patients in groups 1 and 2. It also does not support the use of PORT 326 
alone in any subset. 327 
 328 
Recent publications using the NCDB have provided conflicting results on the value of 329 
PORT after incomplete resection.  Hancock found that chemotherapy or chemotherapy 330 
plus PORT provided superior results for stages I-III.18 However patients who received 331 
PORT alone after incomplete resection had unimproved (stage II-III) or worse (stage I) 332 
survival.  Wang reported slightly longer survival in patients completing a full regime of 333 
PORT at 50-74 Gy post-operatively.25 Key differences in our study may explain the 334 
conflicting results.   335 
 336 
Our analysis of the NCDB used the NCCN adjuvant therapy stage groupings in an 337 
attempt to validate the treatment guidelines. Therefore, we further delineated stage I 338 
patients by pT-category and stage IIA patients by pN-category.  This delineation, 339 
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coupled with the broader timeline (2004-2011 vs. 2003-2006), may explain the subtle 340 
difference between our findings and those of Hancock.18 Both studies found that early-341 
stage patients receiving PORT alone had shorter survival.  However, we found the best 342 
survival for early-stage (NCCN group 2) patients was with chemotherapy alone 343 
compared with Hancock’s findings that chemotherapy with or without PORT both 344 
showed similar survival that was superior to no adjuvant treatment or PORT alone for 345 
the undilineated group of stage II and III patients.18   346 
 347 
The report by Wang, supporting the use of PORT in Stage II-III patients with incomplete 348 
resection, differed from our work by evaluating only patients with an optimal PORT 349 
experience.25 Specifically, Wang excluded all patients who died within 120 days of 350 
surgery, and only included patients who completed optimal-dose radiation. A less 351 
optimal classification of PORT use is more pragmatic and provides better information for 352 
treatment of patients, whose ability to receive a full treatment regime of PORT cannot 353 
be known at the time of treatment decision. Patients who died as a result of acute 354 
radiation complications would have been excluded from their analysis. Another 355 
difference is that they treated chemotherapy as a confounding variable rather than a 356 
separate treatment option as we, and Hancock, have done.  357 
 358 
Our PORT analysis group included all persons who survived 60 days post-surgery and 359 
received treatment with PORT within 6 months of surgery.  Patients who discontinued 360 
PORT or received PORT at a less-than-optimal dose were included to adhere to the 361 
intention-to-treat principle and avoid potential selection bias. Because treatment with 362 
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PORT alone may be carried out differently than PORT with chemotherapy, we 363 
considered these two treatment options separately to better represent clinical practice 364 
and to avoid the potential for residual confounding by controlling for chemotherapy use 365 
exclusively through statistical modeling. 366 
 367 
This retrospective study has several limitations.  We have expressly excluded the 368 
primary recommendation of re-resection for non-R0 resections because of the relatively 369 
small number of such patients in the database. Ideally, PORT is preferably commenced 370 
within 60 days. We used a 6-month eligibility window, as others have done in these 371 
types of analyses, to reflect the practical reality that some patients start adjuvant 372 
therapy late.18,25 The median time to onset of PORT alone was 52 days, and 75% of 373 
patients initiated therapy within 74 days. This suggests that PORT was used adjuvantly, 374 
and not for salvage therapy after disease progression. However, it is impossible to verify 375 
the clinical circumstances around any of the treatments.  376 
 377 
The NCDB covers 70% of all lung cancer cases in the US, drawing from a diverse group 378 
of hospitals.  However, results may not apply directly to substantially different 379 
institutions.  Although the NCDB is thorough, incomplete and inaccurate data are still 380 
potential problems. Although we addressed this limitation for critical variables by 381 
validating our results with sensitivity analyses, unequal assignment of post-operative 382 
treatment modalities may have impacted our results and the sample size of some 383 
analysis subsets may be too small for meaningful statistical inference. Outside a well-384 
executed RCT, this remains a potential explanation for differences observed in all 385 
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studies of this question.  We have addressed this limitation, as well as possible, with 386 
extensive adjustment by statistical analysis.   387 
 388 
The lack of observed benefit from PORT or chemoradiation in early-stage patients after 389 
incomplete resection parallels the current evidence in completely resected patients; the 390 
impact of radiation therapy in reducing the increased cancer-related mortality risk after 391 
incomplete resection does not seem to overcome the excessive treatment-related 392 
mortality risk of PORT.26 Chemotherapy appears to be valuable to some degree across 393 
stage groups; patients with mediastinal nodal metastasis seem to benefit from 394 
chemotherapy or combined-modality chemoradiation.   395 
 396 
Well-conducted retrospective evaluations can lead to conflicting conclusions based on 397 
selection criteria for assigning treatment groups after the fact.  An inherent imbalance 398 
between treatment groups prior to treatment initiation is likely when treatment is 399 
selected based on physician decision after individual patient assessment.  Statistical 400 
adjustment is unlikely to completely eliminate such confounding-by-indication.  401 
 402 
This study provides the most comprehensive evaluation of NCCN guidelines for 403 
postoperative therapy to date.  Results are largely consistent with high-level evidence 404 
available after complete surgical resection.  In patients with incomplete resection, where 405 
the available evidence is far less, these data did not support the use of PORT in early-406 
stage patients.  All available evidence in incompletely-resected patients is lower-level, 407 
and results are discrepant.  Only RCTs can definitively determine the best adjuvant 408 
therapy for incompletely resected NSCLC. 409 
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 410 
Such a trial will be challenging to execute because of the relatively low incidence of 411 
incomplete resections, and the practical reality that incomplete resections are least 412 
frequent in the types of institutions that typically conduct clinical trials.16 However, 413 
infrastructure such as the National Cancer Institute’s Community Oncology Research 414 
Program can be harnessed to support such a trial. The possibility of patient harm in the 415 
existing evidence void should stimulate the political will to resolve this question.  416 
  417 
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Figure legends 547 
 548 
Figure 1.  Study consort diagram for margin positive patients 549 
 550 
Figure 2.  Kaplan Meier survival curves for margin positive patients categorized by 551 
National Comprehensive Cancer Network adjuvant therapy stage groups. The log-rank 552 
p-value tests the null hypothesis that all 4 groups have similar survival. 553 
a.) Group 1- stage IA (T1ab, N0);  554 
b.) Group 2- stage IB (T2a, N0) and Stage IIA (T2b, N0);  555 
c.) Group 3- stage IIA (T1ab-T2a, N1) and stage IIB (T3, N0; T2b N1);  556 
d.) Group 4- stage IIIA (T1-3, N2; T3, N1).   557 
 558 
 559 
Central Figure.  Kaplan Meier Survival Curves for Margin Positive Patients in Stage IB 560 
(T2a, N0) and Stage IIA (T2b, N0).   561 
 562 
 563 
  564 
 565 
 566 
 567 
 568 
 569 
 570 
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Table 1A. Patient Demographic and Institutional Characteristics Among Margin Positive Patients by Stage Group.  
Categories Total 
Stage 
IA(T1ab,N0) 
Stage IB (T2a,N0) 
& IIA (T2b,N0) 
Stage IIA(T1ab-
T2a,N1) & IIB 
Stage IIIA(T1-
T3,N2; T3,N1) 
p-value 
 
N=3461 N=369 N=857 N=1317 N=918 
 N (%) N (%) N (%) N (%) N (%) 
 Age Group 
 18-49 227 (7) 16 (4) 40 (5) 90 (7) 81 (9) < .0001 
50-64 1190 (34) 105 (28) 247 (29) 476 (36) 362 (39) 
 65-74 1230 (36) 141 (38) 328 (38) 458 (35) 303 (33) 
 75-90 814 (24) 107 (29) 242 (28) 293 (22) 172 (19) 
 Sex 
 Male 1851 (53) 159 (43) 436 (51) 766 (58) 490 (53) < .0001 
Female 1610 (47) 210 (57) 421 (49) 551 (42) 428 (47) 
 Race/Ethnicity 
 Non-Hispanic, White 2653 (77) 287 (78) 670 (78) 1000 (76) 696 (76) 0.2 
Hispanic 73 (2) 10 (3) 14 (2) 27 (2) 22 (2) 
 Black 342 (10) 39 (11) 79 (9) 123 (9) 101 (11) 
 Other 88 (3) 6 (2) 16 (2) 48 (4) 18 (2) 
 Missing 305 (9) 27 (7) 78 (9) 119 (9) 81 (9) 
 Insurance 
 Uninsured 87 (3) 6 (2) 19 (2) 40 (3) 22 (2)  < .0001 
Medicaid 176 (5) 15 (4) 36 (4) 63 (5) 62 (7) 
 Younger Medicare 219 (6) 22 (6) 42 (5) 74 (6) 81 (9) 
 Older Medicare 1758 (51) 221 (60) 497 (58) 635 (48) 405 (44) 
 Private 1184 (34) 103 (28) 257 (30) 485 (37) 339 (37) 
 Missing 37 (1) 2 (1) 6 (0) 20 (2) 9 (1) 
 Median Income-Quartile 
 <$30,000 478 (14) 52 (14) 117 (14) 180 (14) 129 (14) 0.84 
$30,000- $34,999 708 (20) 67 (18) 175 (20) 276 (21) 190 (21) 
 $35,000- $45,999 999 (29) 100 (27) 242 (28) 382 (29) 275 (30) 
 $46,000+ 1095 (32) 126 (34) 275 (32) 407 (31) 287 (31) 
 Missing 181 (5) 24 (7) 48 (6) 72 (5) 37 (4) 
 Comorbidity     
0 1611 (47) 144 (39) 387 (45) 623 (47) 457 (50) 0.014 
1 1270 (37) 149 (40) 321 (37) 491 (37) 309 (34) 
 
2+ 580 (17) 76 (21) 149 (17) 203 (15) 152 (17) 
 Histology 
 NOS 9 (0) 1 (0) 1 (0) 7 (1) 0 (0)  < .0001 
Large Cell 177 (5) 14 (4) 34 (4) 70 (5) 59 (6) 
 Squamous 1340 (39) 121 (33) 335 (39) 572 (43) 312 (34) 
 Other 248 (7) 16 (4) 49 (6) 110 (8) 73 (8) 
 Adenocarcinoma 1687 (49) 217 (59) 438 (51) 558 (42) 474 (52) 
 Tumor Grade 
 well/moderately 
differentiated 
1688 (49) 244 (66) 477 (56) 579 (44) 388 (42)  < .0001 
poorly/undifferentiated 1641 (47) 105 (28) 343 (40) 695 (53) 498 (54) 
 Unknown 132 (4) 20 (5) 37 (4) 43 (3) 32 (3) 
 Tumor Size 
 ≤3cm 1339 (39) 356 (96) 279 (33) 418 (32) 286 (31) < .0001 
>3cm-≤5cm 1156 (33) 3 (1) 367 (43) 457 (35) 329 (36) 
 >5cm 940 (27) 8 (2) 207 (24) 428 (33) 297 (32) 
 Unknown 26 (1) 2 (1) 4 (0) 14 (1) 6 (1) 
 Rural/Urban 
 Rural 664 (19) 65 (18) 165 (19) 263 (20) 171 (19) 0.46 
Urban 2582 (75) 279 (76) 631 (74) 970 (74) 702 (76)  
Unknown 215 (6) 25 (7) 61 (7) 84 (6) 45 (5)  
Census Region 
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Northeast 572 (17) 72 (20) 136 (16) 207 (16) 157 (17) 0.58 
Midwest 1100 (32) 108 (29) 283 (33) 409 (31) 300 (33)  
South 1366 (39) 150 (41) 327 (38) 532 (40) 357 (39)  
West 423 (12) 39 (11) 111 (13) 169 (13) 104 (11)  
Primary Site 
 C340- Main bronchus 54 (2) 1 (0) 13 (2) 15 (1) 25 (3) < .0001 
C341-upper lobe 2068 (60) 224 (61) 474 (55) 854 (65) 516 (56) 
 C342-Middle lobe 174 (5) 22 (6) 54 (6) 46 (3) 52 (6) 
 C343-Lower lobe 976 (28) 113 (31) 278 (32) 335 (25) 250 (27) 
 C348-Overlapping lesion 124 (4) 3 (1) 28 (3) 40 (3) 53 (6) 
 C349-Lung NOS 65 (2) 6 (2) 10 (1) 27 (2) 22 (2) 
 T category 
 T1 676 (20) 369 (100) 0 (0) 184 (14) 123 (13) < .0001 
T2 1773 (51) 0 (0) 857 (100) 536 (41) 380 (41) 
 T3 1012 (29) 0 (0) 0 (0) 597 (45) 415 (45) 
 N Category 
 N0 1823 (53) 369 (100) 857 (100) 597 (45) 0 (0) < .0001 
N1 964 (28) 0 (0) 0 (0) 720 (55) 244 (27) 
 N2 674 (19) 0 (0) 0 (0) 0 (0) 674 (73) 
 Surgery 
 Sublobar 420 (12) 114 (31) 95 (11) 109 (8) 102 (11) < .0001 
Lobe/bilobectomy 2643 (76) 250 (68) 703 (82) 1060 (80) 630 (69) 
 Pneumonectomy 398 (12) 5 (1) 59 (7) 148 (11) 186 (20) 
 Facility type 
 Community Cancer Program 329 (10) 31 (8) 75 (9) 139 (11) 84 (9) 0.75 
Comprehensive Community 
Cancer Program 
1772 (51) 191 (52) 445 (52) 679 (52) 457 (50) 
 Teaching/Research Cancer 
Program 
738 (21) 79 (21) 188 (22) 274 (21) 197 (22) 
 NCI Program/Network 299 (9) 39 (11) 72 (8) 104 (8) 84 (9) 
 Other 323 (9) 29 (8) 77 (9) 121 (9) 96 (10)   
 
Table 1B. Patient Demographic and Institutional Characteristics Among Margin Positive Patients by Adjuvant Therapy.  
Categories Total No Treatment Chemotherapy Radiation therapy Chemoradiation p-value 
 
N=3461 N=1406 N=645 N=447 N=963 
 N (%) N (%) N (%) N (%) N (%) 
 Stage Group 
     
Stage IA 369 (11) 265 (19) 19 (3) 60 (13) 25 (3) < .0001 
Stage IB & IIA 857 (25) 477 (34) 142 (22) 119 (27) 119 (12) 
 Stage IIA & IIB 1317 (38) 419 (30) 284 (44) 199 (45) 415 (43) 
 Stage IIIA 918 (27) 245 (17) 200 (31) 69 (15) 404 (42) 
 Age Group 
 18-49 227 (7) 66 (5) 44 (7) 14 (3) 103 (11) < .0001 
50-64 1190 (34) 390 (28) 271 (42) 106 (24) 423 (44) 
 65-74 1230 (36) 508 (36) 227 (35) 170 (38) 325 (34) 
 75-90 814 (24) 442 (31) 103 (16) 157 (35) 112 (12) 
 Sex 
 Male 1851 (53) 735 (52) 337 (52) 240 (54) 539 (56) 0.31 
Female 1610 (47) 671 (48) 308 (48) 207 (46) 424 (44) 
 Race/Ethnicity 
 Non-Hispanic, White 2653 (77) 1087 (77) 475 (74) 350 (78) 741 (77) 0.18 
Hispanic 73 (2) 35 (2) 15 (2) 8 (2) 15 (2) 
 Black 342 (10) 147 (10) 67 (10) 34 (8) 94 (10) 
 Other 88 (3) 29 (2) 18 (3) 17 (4) 24 (2) 
 Missing 305 (9) 108 (8) 70 (11) 38 (9) 89 (9) 
 Insurance 
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Uninsured 87 (3) 37 (3) 14 (2) 9 (2) 27 (3)  < .0001 
Medicaid 176 (5) 69 (5) 23 (4) 23 (5) 61 (6) 
 Younger Medicare 219 (6) 77 (5) 44 (7) 16 (4) 82 (9) 
 Older Medicare 1758 (51) 823 (59) 275 (43) 296 (66) 364 (38) 
 Private 1184 (34) 388 (28) 281 (44) 96 (21) 419 (44) 
 Missing 37 (1) 12 (1) 8 (1) 7 (2) 10 (1) 
 Median Income-Quartile 
 <$30,000 478 (14) 196 (14) 79 (12) 72 (16) 131 (14) 0.25 
$30,000- $34,999 708 (20) 281 (20) 139 (22) 81 (18) 207 (22) 
 $35,000- $45,999 999 (29) 405 (29) 171 (27) 132 (30) 291 (30) 
 $46,000+ 1095 (32) 448 (32) 211 (33) 139 (31) 297 (31) 
 Missing 181 (5) 76 (5) 45 (7) 23 (5) 37 (4) 
 Comorbidity     
0 1611 (47) 634 (45) 331 (51) 183 (41) 463 (48) 0.005 
1 1270 (37) 511 (36) 225 (35) 179 (40) 355 (37) 
 
2+ 580 (17) 261 (19) 89 (14) 85 (19) 145 (15) 
 Histology 
 NOS 9 (0) 3 (0) 2 (0) 1 (0) 3 (0) 
 Large Cell 177 (5) 57 (4) 38 (6) 23 (5) 59 (6)  < .0001 
Squamous 1340 (39) 524 (37) 214 (33) 216 (48) 386 (40) 
 Other 248 (7) 90 (6) 46 (7) 32 (7) 80 (8) 
 Adenocarcinoma 1687 (49) 732 (52) 345 (53) 175 (39) 435 (45) 
 Tumor Grade 
 well/moderately 
differentiated 
1688 (49) 753 (54) 307 (48) 208 (47) 420 (44) 
 poorly/undifferentiated 1641 (47) 590 (42) 312 (48) 221 (49) 518 (54)  < .0001 
Unknown 132 (4) 63 (4) 26 (4) 18 (4) 25 (3) 
 Tumor Size 
 ≤3cm 1339 (39) 654 (47) 212 (33) 172 (38) 301 (31) 
 >3cm-≤5cm 1156 (33) 417 (30) 223 (35) 161 (36) 355 (37) < .0001 
>5cm 940 (27) 323 (23) 207 (32) 112 (25) 298 (31) 
 Unknown 26 (1) 12 (1) 3 (0) 2 (0) 9 (1) 
 Rural/Urban 
 Rural 664 (19) 285 (20) 110 (17) 90 (20) 179 (19) 0.014 
Urban 2582 (75) 1023 (73) 482 (75) 337 (75) 740 (77)  
Unknown 215 (6) 98 (7) 53 (8) 20 (4) 44 (5)  
Census Region 
 Northeast 572 (17) 234 (17) 106 (16) 79 (18) 153 (16) < .0001 
Midwest 1100 (32) 386 (27) 222 (34) 144 (32) 348 (36)  
South 1366 (39) 586 (42) 246 (38) 158 (35) 376 (39)  
West 423 (12) 200 (14) 71 (11) 66 (15) 86 (9)  
Primary Site 
 C340- Main bronchus 54 (2) 16 (1) 8 (1) 12 (3) 18 (2) 0.22 
C341-upper lobe 2068 (60) 825 (59) 384 (60) 280 (63) 579 (60) 
 C342-Middle lobe 174 (5) 76 (5) 34 (5) 14 (3) 50 (5) 
 C343-Lower lobe 976 (28) 412 (29) 185 (29) 122 (27) 257 (27) 
 C348-Overlapping lesion 124 (4) 45 (3) 22 (3) 16 (4) 41 (4) 
 C349-Lung NOS 65 (2) 32 (2) 12 (2) 3 (1) 18 (2) 
 T category 
 T1 676 (20) 368 (26) 82 (13) 89 (20) 137 (14) < .0001 
T2 1773 (51) 757 (54) 388 (60) 191 (43) 437 (45) 
 T3 1012 (29) 281 (20) 175 (27) 167 (37) 389 (40) 
 N Category 
 N0 1823 (53) 912 (65) 247 (38) 309 (69) 355 (37) < .0001 
N1 964 (28) 320 (23) 248 (38) 94 (21) 302 (31) 
 N2 674 (19) 174 (12) 150 (23) 44 (10) 306 (32) 
 Surgery 
 Sublobar 420 (12) 180 (13) 56 (9) 78 (18) 106 (11) < .0001 
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Lobe/bilobectomy 2643 (76) 1077 (77) 482 (75) 335 (75) 749 (78) 
 Pneumonectomy 398 (12) 149 (11) 107 (17) 34 (8) 108 (11) 
 Facility type 
 Community Cancer Program 329 (10) 123 (9) 55 (9) 33 (7) 118 (12) < .0001 
Comprehensive Community 
Cancer Program 
1772 (51) 687 (49) 328 (51) 249 (56) 508 (53) 
 Teaching/Research Cancer 
Program 
738 (21) 343 (24) 131 (20) 97 (22) 167 (17) 
 NCI Program/Network 299 (9) 133 (9) 66 (10) 32 (7) 68 (7) 
 Other 323 (9) 120 (9) 65 (10) 36 (8) 102 (11)   
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Table 2.   Kaplan Meier Survival Analysis and Proportional Hazards Models by Stage Group for Margin Positive Patients.  
  
  Margin Positive 
  
Post-Op 
Treatment N 
5 Year Overall 
Survival (%) 
(Logrank P-Value*) 
Unadjusted 
Hazard Ratio   
(95% CI) 
Adjusted Hazard 
Ratio**  
(95% CI) 
P-Value* 
Group 1: Stage IA (T1ab, N0) 
No Treatment 265 58 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 19 65 (0.6687) 0.81 (0.35-1.86) 1.27 (0.48-3.38) 0.6369 
Radiation Only 60 26 (0.0030) 1.97 (1.25-3.11) 1.68 (0.99-2.84) 0.0551 
Chemo + Rad 25 35 (0.0895) 1.69 (0.92-3.12) 0.96 (0.47-1.98) 0.9176 
Group 2: Stage IB  (T2a, N0) &                   
Stage IIA (T2b, N0) 
No Treatment 477 47 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 142 62 (0.0065) 0.61 (0.43-0.87) 0.58 (0.40-0.84) 0.004 
Radiation Only 119 25 (0.0251) 1.39 (1.04-1.86) 1.28 (0.94-1.74) 0.1185 
Chemo + Rad 119 39 (0.3571) 1.15 (0.85-1.57) 0.97 (0.70-1.35) 0.8678 
Group 3: Stage IIA (T1ab-T2a, N1) & 
Stage IIB (T3, N0;T2b N1) 
No Treatment 419 27 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 284 36 (0.0001) 0.65 (0.53-0.81) 0.72 (0.58-0.90) 0.0041 
Radiation Only 199 26 (0.5907) 1.06 (0.85-1.32) 0.94 (0.74-1.18) 0.5878 
Chemo + Rad 415 37 (<.0001) 0.68 (0.56-0.83) 0.76 (0.62-0.93) 0.0083 
Group 4: Stage IIIA (T1-3, N2; T3, N1) 
No Treatment 245 12 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 200 21 (0.0048) 0.70 (0.55-0.90) 0.77 (0.60-1.00) 0.0466 
Radiation Only 69 10 (0.5215) 1.11 (0.81-1.51) 1.03 (0.74-1.43) 0.8729 
Chemo + Rad 404 25 (<.0001) 0.59 (0.48-0.72) 0.63 (0.51-0.79) <.0001 
*P-values compare each treatment to referent (no treatment) **Adjusted for Age, Sex, Race/Ethnicity, Insurance, Median Income, Comorbidity, Histology, Tumor 
Grade, Tumor Size, Rural/Urban, Census Region, Primary Site, T Category, N Category, Surgery Facility type, Facility Surgical % Lung Cancer, Facility % 
Medicaid or Uninsured 
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Table 3.   Kaplan Meier Survival Analysis and Proportional Hazards Models by Stage Group for Margin Negative Patients.  
  
  Margin Negative 
  
Post-Op 
Treatment N 
5 Year Overall 
Survival (%) 
(log-rank P-Value*) 
Unadjusted 
Hazard Ratio   
(95% CI) 
Adjusted 
Hazard Ratio** 
(95% CI) 
P-Value* 
Group 1: Stage IA (T1ab, N0) 
No Treatment 33780 71 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 789 74 (0.2946) 0.92 (0.78-1.08) 1.02 (0.87-1.20) 0.816 
Radiation Only 136 44 (<.0001) 2.89 (2.22-3.73) 2.18 (1.67-2.85) <.0001 
Chemo + Rad 76 40 (<.0001) 3.19 (2.21-4.59) 2.99 (2.07-4.31) <.0001 
Group 2: Stage IB  (T2a, N0) &                   
Stage IIA (T2b, N0) 
No Treatment 19281 57 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 4568 68 (<.0001) 0.68 (0.63-0.72) 0.74 (0.69-0.80) <.0001 
Radiation Only 250 38 (<.0001) 1.92 (1.60-2.31) 1.8 (1.49-2.16) <.0001 
Chemo + Rad 215 47 (0.0003) 1.47 (1.19-1.81) 1.41 (1.14-1.74) 0.0016 
Group 3: Stage IIA (T1ab-T2a, N1) & 
 Stage IIB (T3, N0;T2b N1) 
No Treatment 6101 37 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 5788 53 (<.0001) 0.59 (0.56-0.63) 0.66 (0.62-0.70) <.0001 
Radiation Only 354 28 (<.0001) 1.35 (1.17-1.57) 1.36 (1.18-1.58) <.0001 
Chemo + Rad 895 40 (0.1772) 0.93 (0.84-1.03) 1.04 (0.93-1.16) 0.4811 
Group 4: Stage IIIA (T1-3, N2; T3, N1) 
No Treatment 2119 24 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 2520 39 (<.0001) 0.59 (0.55-0.65) 0.63 (0.58-0.69) <.0001 
Radiation Only 248 18 (0.0747) 1.18 (0.99-1.39) 1.15 (0.97-1.37) 0.1025 
Chemo + Rad 1859 38 (<.0001) 0.62 (0.57-0.68) 0.69 (0.63-0.76) <.0001 
*P-values compare each treatment to referent (no treatment) **Adjusted for Age, Sex, Race/Ethnicity, Insurance, Median Income, Comorbidity, Histology, Tumor 
Grade, Tumor Size, Rural/Urban, Census Region, Primary Site, T Category, N Category, Surgery Facility type, Facility Surgical % Lung Cancer, Facility % 
Medicaid or Uninsured 
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Table 4. Comparative survival impact of post-operative adjuvant therapy in patients with completely and incompletely 
resected stage I – IIIA NSCLC in the NCDB, current NCCN adjuvant therapy recommendations (‘recs’), and objective 
results from our analysis.  
 
 
Stage Margin Status Chemo Radiation chemoXRT NCCN NCDB Data 
Group 1: Stage IA Negative Neutral Worse Worse Observe Supports observation Positive Neutral Worse Neutral Radiation Supports Observation 
 
Group 2: 
Stage IB & Stage 
IIA 
Negative Better Worse Worse Observe or Chemo Supports Chemo Only 
Positive Better Neutral Neutral RT+/-Chemo Supports Chemo Only 
 
Group 3: Stage IIA 
& Stage IIB 
Negative Better Worse Neutral Chemo Supports Chemo Only 
Positive Better Neutral Better 
 
R1 Better Neutral Better Chemo+RT Supports Chemo+/-RT 
R2 Insufficient Data (Supplemental Table I) Chemo+RT 
 
 
Group 4: Stage 
IIIA 
Negative Better Neutral Better 
 
Non-N2 Better Neutral Neutral Chemo Supports chemo only 
N2 Better Worse Better Chemo+RT Supports Chemo+/-RT 
 
Group 4: Stage 
IIIA 
Positive Better Neutral Better 
R1 Neutral Neutral Better Chemo+RT Supports chemo+RT 
R2 Insufficient Data (Supplemental Table I) 
  
 
 
Chemo= chemotherapy; RT= radiation therapy; Chemo+RT= combined-modality chemotherapy and radiation therapy.  
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Supplemental Tables and Figures: 
Supplemental Table I. Times from Surgery to Adjuvant Therapy 
Supplemental Table IIA. Patient Demographic and Institutional Characteristics Among Margin 
Negative Patients by Stage Group.  
Supplemental Table IIB. Patient Demographic and Institutional Characteristics Among Margin 
Negative Patients by Adjuvant Therapy.  
Supplemental Table III. Propensity Score Adjusted Models 
Supplemental Table IV.  Proportional Hazards Models by Stage Group and Margin Status After 
removal of exposure groups where the Proportional Hazards assumption is questionable. 
Supplemental Table V.   Kaplan Meier Survival Analysis and Proportional Hazards Models by 
Stage Group for Margin Positive Patients Evaluating the Order of Chemotherapy and Radiation.  
Supplemental Table VI. Survival results for Margin Positive Patients by R1, R2, and R-Unknown  
Supplemental Table VII.  Analysis of Stage Group 4, Margin negative patients by pN stage 
(N0/N1 vs. N2)  
Supplemental Table VIII.   Kaplan Meier Survival Analysis and Proportional Hazards Models by 
Stage Group for Margin Negative Patients Evaluating the Order of Chemotherapy and 
Radiation. 
Supplemental Table IX. Analysis including only Anatomic Resections 
Supplemental Table X.  Numbers of Events in Each Analysis Group 
Supplemental Figure I.  Consort Diagram for Margin Negative 
Supplemental Figure II.  Kaplan Meier Survival Curves for Margin Negative Patients by Stage 
Group 
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Supplemental Table I. Times from Surgery to Adjuvant Therapy 
  
Median IQR 
Days from surgery to initiation of PORT in patients without 
chemotherapy  52 39-74 
Days from surgery to initiation of chemotherapy in patients without 
PORT 47 35-62 
In Patients receiving chemotherapy and PORT     
Days from surgery to initiation of radiation therapy  57 40-126 
Days from surgery to initiation of chemotherapy  43 34-58 
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Supplemental Table IIA. Patient Demographic and Institutional Characteristics Among 
Margin Negative Patients by Stage Group.  
 
Categories Total 
Stage 
IA(T1ab,N0
) 
Stage IB 
(T2a,N0) & 
IIA (T2b,N0) 
Stage 
IIA(T1ab-
T2a,N1) & 
IIB 
Stage 
IIIA(T1-
T3,N2; 
T3,N1) 
p-value 
N=78979 N=34781 N=24314 N=13138 N=6746 
N (%) N (%) N (%) N (%) N (%) 
Age Group 
18-49 4389 (6) 1870 (5) 1181 (5) 820 (6) 518 (8) < .0001 
50-64 25864 (33) 11380 (33) 7352 (30) 4651 (35) 2481 (37) 
65-74 29782 (38) 13462 (39) 9084 (37) 4871 (37) 2365 (35) 
75-90 18944 (24) 8069 (23) 6697 (28) 2796 (21) 1382 (21) 
Sex 
Male 37844 (48) 14933 (43) 12480 (51) 7055 (54) 3376 (50) < .0001 
Female 41135 (52) 19848 (57) 11834 (49) 6083 (46) 3370 (50) 
Race/Ethnicity 
Non-Hispanic, White 61957 (79) 27532 (79) 18978 (78) 10303 (78) 5144 (76) < .0001 
Hispanic 1734 (2) 709 (2) 565 (2) 278 (2) 182 (3) 
Black 6478 (8) 2665 (8) 2029 (8) 1124 (9) 660 (10) 
Other 2078 (3) 879 (3) 657 (3) 322 (3) 220 (3) 
Missing 6732 (9) 2996 (9) 2085 (9) 1111 (9) 540 (8) 
Insurance 
Uninsured 1517 (2) 563 (2) 493 (2) 286 (2) 175 (3)  < .0001 
Medicaid 3325 (4) 1301 (4) 1030 (4) 635 (5) 359 (5) 
Younger Medicare 4538 (6) 2120 (6) 1278 (5) 745 (6) 395 (6) 
Older Medicare 41134 (52) 18298 (53) 13253 (55) 6452 (49) 3131 (46) 
Private 27402 (35) 12033 (35) 7946 (33) 4828 (37) 2595 (39) 
Missing 1063 (1) 466 (1) 314 (1) 192 (2) 91 (1) 
Median Income-Quartile 
<$30,000 10308 (13) 4326 (12) 3287 (14) 1810 (14) 885 (13)  < .0001 
$30,000- $34,999 14718 (19) 6277 (18) 4619 (19) 2574 (20) 1248 (19) 
$35,000- $45,999 21718 (28) 9454 (27) 6705 (28) 3723 (28) 1836 (27) 
$46,000+ 27950 (35) 12742 (37) 8414 (35) 4397 (34) 2397 (36) 
Missing 4285 (5) 1982 (6) 1289 (5) 634 (5) 380 (6) 
Comorbidity     
0 37470 (47) 16095 (46) 11671 (48) 6293 (48) 3411 (51)  < .0001 
1 28532 (36) 12865 (37) 8532 (35) 4818 (37) 2317 (34) 
 2+ 12977 (16) 5821 (17) 4111 (17) 2027 (15) 1018 (15) 
Histology 
NOS 224 (0.3) 93 (0.3) 67 (0.3) 45 (0.3) 19 (0.3)  < .0001 
Large Cell 3652 (5) 1358 (4) 1225 (5) 695 (5) 374 (6) 
Squamous 22791 (29) 8584 (25) 8069 (33) 4390 (33) 1748 (26) 
Other 4030 (5) 1604 (5) 1254 (5) 781 (6) 391 (6) 
Adenocarcinoma 48282 (61) 23142 (67) 13699 (56) 7227 (55) 4214 (63) 
Tumor Grade 
well/moderately 
differentiated 46558 (59) 23274 (67) 13619 (56) 6519 (50) 3146 (47)  < .0001 
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poorly/undifferentiated 29030 (37) 9788 (28) 9699 (40) 6195 (47) 3348 (50) 
Unknown 3391 (4) 1719 (5) 996 (4) 424 (3) 252 (4) 
Tumor Size 
≤3cm 49644 (63) 34452 (99) 6486 (27) 5711 (44) 2995 (44) < .0001 
>3cm-≤5cm 19238 (24) 167 (0.5) 12819 (53) 4188 (32) 2064 (31) 
>5cm 9866 (13) 97 (0.3) 4932 (20) 3175 (24) 1662 (25) 
Unknown 231 (0.3) 65 (0.2) 77 (0.3) 64 (0.5) 25 (0.4) 
Rural/Urban 
Rural 14999 (19) 6312 (18) 4720 (19) 2686 (20) 1281 (19) < .0001 
Urban 59057 (75) 26236 (75) 18097 (74) 9680 (74) 5044 (75)  
Unknown 4923 (6) 2233 (6) 1497 (6) 772 (6) 421 (6)  
Census Region 
Northeast 15939 (20) 7486 (22) 4727 (19) 2374 (18) 1352 (20) < .0001 
Midwest 21583 (27) 9160 (26) 6732 (28) 3787 (29) 1904 (28)  
South 31840 (40) 13980 (40) 9752 (40) 5417 (41) 2691 (40)  
West 9617 (12) 4155 (12) 3103 (13) 1560 (12) 799 (12)  
Primary Site 
C340- Main bronchus 431 (1) 46 (0.1) 95 (0.4) 199 (2) 91 (1) < .0001 
C341-upper lobe 47385 (60) 21947 (63) 13929 (57) 7547 (57) 3962 (59) 
C342-Middle lobe 3819 (5) 1880 (5) 1119 (5) 562 (4) 258 (4) 
C343-Lower lobe 25061 (32) 10323 (30) 8340 (34) 4249 (32) 2149 (32) 
C348-Overlapping lesion 1191 (2) 199 (0.6) 467 (2) 352 (3) 173 (3) 
C349-Lung NOS 1092 (1) 386 (1) 364 (2) 229 (2) 113 (2) 
T category 
T1 40403 (51) 34781 (100) 0 (0) 3716 (28) 1906 (28) < .0001 
T2 33968 (43) 0 (0) 24314 (100) 6360 (48) 3294 (49) 
T3 4608 (6) 0 (0) 0 (0) 3062 (23) 1546 (23) 
N Category 
N0 62157 (79) 34781 (100) 24314 (100) 3062 (23) 0 (0) < .0001 
N1 11108 (14) 0 (0) 0 (0) 10076 (77) 1032 (15) 
N2 5714 (7) 0 (0) 0 (0) 0 (0) 5714 (85) 
Surgery 
Sublobar 7992 (10) 5005 (14) 1797 (7) 599 (5) 591 (9) < .0001 
Lobe/bilobectomy 67209 (85) 29544 (85) 21515 (89) 10907 (83) 5243 (78) 
Pneumonectomy 3778 (5) 232 (1) 1002 (4) 1632 (12) 912 (14) 
Facility type 
Community Cancer 
Program 5707 (7) 2505 (7) 1746 (7) 1011 (8) 445 (7) 0.0005 
Comprehensive 
Community Cancer 
Program 
37952 (48) 16705 (48) 11724 (48) 6387 (49) 3136 (47) 
Teaching/Research 
Cancer Program 19304 (24) 8490 (24) 5892 (24) 3162 (24) 1760 (26) 
NCI Program/Network 8954 (11) 4052 (12) 2738 (11) 1395 (11) 769 (11) 
Other 7062 (9) 3029 (9) 2214 (9) 1183 (9) 636 (9)   
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Supplemental Table IIB. Patient Demographic and Institutional Characteristics Among 
Margin Negative Patients by Adjuvant Therapy.  
 
Categories Total 
No 
Treatmen
t 
Chemother
apy 
Radiation 
therapy 
Chemoradiat
ion 
p-
value 
N=78979 N=61281 N=13665 N=988 N=3045 
N (%) N (%) N (%) N (%) N (%) 
Stage Group 
     
Stage IA 34781 (44) 
33780 
(55) 789 (6) 136 (14) 76 (3) 
< 
.0001 
Stage IB & IIA 24314 (31) 
19281 
(32) 4568 (33) 250 (25) 215 (7) 
Stage IIA & IIB 13138 (17) 6101 (10) 5788 (42) 354 (36) 895 (29) 
Stage IIIA 6746 (9) 2119 (4) 2520 (18) 248 (25) 1859 (61) 
Age Group 
18-49 4389 (6) 2882 (5) 1114 (8) 56 (6) 337 (11) < 
.0001 
50-64 25864 (33) 
18296 
(30) 5962 (44) 261 (26) 1345 (44) 
65-74 29782 (38) 
23397 
(38) 4981 (37) 382 (39) 1022 (34) 
75-90 18944 (24) 
16706 
(27) 1608 (12) 289 (29) 341 (11) 
Sex 
Male 37844 (48) 
28854 
(47) 6856 (50) 547 (55) 1587 (52) 
< 
.0001 
Female 41135 (52) 
32427 
(53) 6809 (50) 441 (45) 1458 (48) 
Race/Ethnicity 
Non-Hispanic, 
White 
61957 
(79) 
48361 
(79) 10515 (77) 758 (77) 2323 (76) 
< 
.0001 
Hispanic 1734 (2) 1356 (2) 297 (2) 17 (2) 64 (2) 
Black 6478 (8) 4803 (8) 1293 (10) 96 (10) 286 (9) 
Other 2078 (3) 1616 (3) 346 (3) 28 (3) 88 (3) 
Missing 6732 (9) 5145 (8) 1214 (9) 89 (9) 284 (9) 
Insurance 
Uninsured 1517 (2) 1091 (2) 341 (3) 16 (2) 69 (2)  < 
.0001 
Medicaid 3325 (4) 2382 (4) 720 (5) 51 (5) 172 (6) 
Younger 
Medicare 4538 (6) 3413 (6) 849 (6) 59 (6) 217 (7) 
Older Medicare 41134 (52) 
33907 
(55) 5528 (41) 576 (58) 1123 (37) 
Private 27402 (35) 
19609 
(32) 6083 (45) 277 (28) 1433 (47) 
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Missing 1063 (1) 879 (1) 144 (1) 9 (1) 31 (1) 
Median Income-Quartile 
<$30,000 10308 (13) 7968 (13) 1808 (13) 158 (16) 374 (12) 
 < 
.0001 
$30,000- $34,999 14718 (19) 
11386 
(19) 2498 (18) 221 (22) 613 (20) 
$35,000- $45,999 21718 (28) 
16705 
(27) 3878 (28) 270 (27) 865 (28) 
$46,000+ 27950 (35) 
21822 
(36) 4807 (35) 300 (30) 1021 (34) 
Missing 4285 (5) 3400 (6) 674 (5) 39 (4) 172 (6) 
Comorbidity     
0 37470 (47) 
28612 
(47) 6848 (50) 438 (44) 1572 (52) 
 < 
.0001 
1 28532 (36) 
22149 
(36) 4945 (36) 364 (37) 1074 (35)  
2+ 12977 (16) 
10520 
(17) 1872 (14) 186 (19) 399 (13) 
Histology 
NOS 224 (0.3) 175 (0.3) 36 (0.3) 2 (0.2) 11 (0.4)  < 
.0001 
Large Cell 3652 (5) 2581 (4) 821 (6) 64 (7) 186 (6) 
Squamous 22791 (29) 
17710 
(29) 3897 (29) 383 (39) 801 (26) 
Other 4030 (5) 3031 (5) 739 (5) 62 (6) 198 (7) 
Adenocarcinoma 48282 (61) 
37784 
(62) 8172 (60) 477 (48) 1849 (61) 
Tumor Grade 
well/moderately 
differentiated 
46558 
(59) 
37923 
(62) 6827 (50) 496 (50) 1312 (43) 
 < 
.0001 
poorly/undifferenti
ated 
29030 
(37) 
20626 
(34) 6356 (47) 449 (46) 1599 (53) 
Unknown 3391 (4) 2732 (5) 482 (4) 43 (4) 134 (4) 
Tumor Size 
≤3cm 49644 (63) 
42437 
(69) 5367 (39) 448 (45) 1392 (46) 
< 
.0001 
>3cm-≤5cm 19238 (24) 
13070 
(21) 4923 (36) 324 (33) 921 (30) 
>5cm 9866 (13) 5600 (9) 3335 (24) 210 (21) 721 (24) 
Unknown 231 (0.3) 174 (0.3) 40 (0.3) 6 (0.6) 11 (0.4) 
Rural/Urban 
Rural 14999 (19) 
11672 
(19) 2540 (19) 196 (20) 591 (19) 0.034 
Urban 59057 (75) 
45716 
(75) 10335 (76) 746 (76) 2260 (74) 
 
Unknown 4923 (6) 3893 (6) 790 (6) 46 (5) 194 (6)  
Census Region 
Northeast 15939 (20) 
12446 
(20) 2734 (20) 161 (16) 598 (20) 
< 
.0001 
Midwest 21583 (27) 
15988 
(26) 4355 (32) 268 (27) 972 (32) 
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South 31840 (40) 
24965 
(41) 5215 (38) 432 (44) 1228 (40) 
 
West 9617 (12) 7882 (13) 1361 (10) 127 (13) 247 (8)  
Primary Site 
C340- Main 
bronchus 431 (1) 250 (0.4) 152 (1) 6 (1) 23 (1) 
< 
.0001 
C341-upper lobe 47385 (60) 
36984 
(60) 7838 (57) 626 (63) 1937 (64) 
C342-Middle lobe 3819 (5) 3024 (5) 617 (5) 40 (4) 138 (5) 
C343-Lower lobe 25061 (32) 
19451 
(32) 4509 (33) 278 (28) 823 (27) 
C348-Overlapping 
lesion 1191 (2) 768 (1) 333 (2) 19 (2) 71 (2) 
C349-Lung NOS 1092 (1) 804 (1) 216 (2) 19 (2) 53 (2) 
T category 
T1 40403 (51) 
35961 
(59) 3285 (24) 261 (26) 896 (29) 
< 
.0001 
T2 33968 (43) 
23130 
(38) 8800 (64) 494 (50) 1544 (51) 
T3 4608 (6) 2190 (4) 1580 (12) 233 (24) 605 (20) 
N Category 
N0 62157 (79) 
54703 
(89) 6292 (46) 565 (57) 597 (20) 
< 
.0001 
N1 11108 (14) 4855 (8) 5317 (39) 210 (21) 726 (24) 
N2 5714 (7) 1723 (3) 2056 (15) 213 (22) 1722 (57) 
Surgery 
Sublobar 7992 (10) 6738 (11) 718 (5) 169 (17) 367 (12) < 
.0001 
Lobe/bilobectomy 67209 (85) 
52526 
(86) 11513 (84) 744 (75) 2426 (80) 
Pneumonectomy 3778 (5) 2017 (3) 1434 (11) 75 (8) 252 (8) 
Facility type 
Community 
Cancer Program 5707 (7) 4283 (7) 1023 (8) 112 (11) 289 (10) 
< 
.0001 
Comprehensive 
Community 
Cancer Program 
37952 
(48) 
29420 
(48) 6456 (47) 500 (51) 1576 (52) 
Teaching/Researc
h Cancer 
Program 
19304 
(24) 
15141 
(25) 3235 (24) 214 (22) 714 (24) 
NCI 
Program/Network 8954 (11) 7039 (12) 1657 (12) 67 (7) 191 (6) 
Other 7062 (9) 5398 (9) 1294 (10) 95 (10) 275 (9)   
 
 
 
Supplemental Table III. Propensity Score Adjusted Models 
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  Margin Positive 
 
Margin Negative 
  
Post-Op 
Treatment N 
Propensity 
Adjusted 
Hazard Ratio  
(95% CI) 
P-Value 
 
N 
Propensity 
Adjusted Hazard 
Ratio  (95% CI) 
P-Value 
Group 1: 
Stage IA 
(T1ab, N0) 
No Treatment 265 1.00 (Referent) 
  
33780 1.00 (Referent) 
 Chemo Only 19 0.94 (0.36-2.44) 0.8968 
 
789 1.02 (0.87-1.20) 0.7841 
Radiation Only 60 1.87 (1.16-3.04) 0.011 
 
136 2.37 (1.81-3.09) <.0001 
Chemo + Rad 25 1.39 (0.73-2.63) 0.3142   76 2.91 (2.02-4.19) <.0001 
         Group 2: 
Stage IB  
(T2a, N0) 
&                   
Stage IIA 
(T2b, N0) 
No Treatment 477 1.00 (Referent) 
  
19281 1.00 (Referent) 
 Chemo Only 142 0.58 (0.40-0.83) 0.0032 
 
4568 0.73 (0.68-0.78) <.0001 
Radiation Only 119 1.30 (0.97-1.73) 0.0818 
 
250 1.79 (1.49-2.16) <.0001 
Chemo + Rad 119 1.01 (0.73-1.39) 0.9688   215 1.42 (1.15-1.76) 0.0012 
         Group 3: 
Stage IIA 
(T1ab-T2a, 
N1) & 
Stage IIB 
(T3, 
N0;T2b 
N1) 
No Treatment 419 1.00 (Referent) 
  
6101 1.00 (Referent) 
 Chemo Only 284 0.73 (0.59-0.91) 0.0058 
 
5788 0.66 (0.62-0.71) <.0001 
Radiation Only 199 1.02 (0.81-1.28) 0.8649 
 
354 1.37 (1.19-1.59) <.0001 
Chemo + Rad 415 0.78 (0.64-0.97) 0.0218 
 
895 1.05 (0.95-1.18) 0.341 
Chemo+Rad 146 0.81 (0.61-1.07) 0.1343 
 
431 1.04 (0.89-1.20) 0.6584 
Rad+Chemo 120 0.77 (0.57-1.06) 0.1054 
 
224 1.12 (0.93-1.37) 0.24 
Chemo=Rad 149 0.80 (0.59-1.07) 0.1344   240 1.06 (0.86-1.29) 0.5967 
         Group 4: 
Stage IIIA 
(T1-3, N2; 
T3, N1) 
No Treatment 245 1.00 (Referent) 
  
2119 1.00 (Referent) 
 Chemo Only 200 0.74 (0.58-0.95) 0.0167 
 
2520 0.64 (0.58-0.69) <.0001 
Radiation Only 69 1.13 (0.83-1.54) 0.4428 
 
248 1.17 (0.98-1.38) 0.0757 
Chemo + Rad 404 0.67 (0.54-0.83) 0.0003 
 
1859 0.71 (0.65-0.79) <.0001 
Chemo+Rad 173 0.59 (0.45-0.77) 0.0001 1096 0.64 (0.56-0.71) <.0001 
Rad+Chemo 96 0.79 (0.57-1.09) 0.1434 316 0.77 (0.65-0.92) 0.0038 
  Chemo=Rad 135 0.59 (0.44-0.80) 0.0006   447 0.78 (0.67-0.90) 0.001 
 
 
 
 
 
 
 
 
 
Supplemental Table IV.  Proportional Hazards Models by Stage Group and Margin Status 
After removal of exposure groups where the Proportional Hazards assumption is 
questionable. 
  
  Margin Positive 
  
Post-Op Treatment N Unadjusted Hazard Ratio   (95% CI) 
Adjusted Hazard 
Ratio (95% CI) P-Value 
Group 1: Stage No Treatment 265 1.00 (Referent) 1.00 (Referent) 
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IA (T1ab, N0) Chemo Only (patients who had chemotherapy only were excluded from the analysis) 
Radiation Only 60 1.98 (1.25-3.12) 1.75 (1.03-2.97) 0.0385 
Chemo + Rad 25 1.69 (0.92-3.11) 0.92 (0.44-1.92) 0.8202 
      Group 3: Stage 
IIA (T1ab-T2a, 
N1) & Stage IIB 
(T3, N0;T2b N1) 
No Treatment 419 1.00 (Referent) 1.00 (Referent) 
 Chemo Only 284 0.65 (0.53-0.81) 0.72 (0.58-0.90) 0.0042 
Radiation Only (patients who had radiation therapy only were excluded from the analysis) 
Chemo + Rad 415 0.68 (0.56-0.83) 0.77 (0.63-0.95) 0.0148 
 
 
Supplemental Table V.   Kaplan Meier Survival Analysis and Proportional Hazards Models 
by Stage Group for Margin Positive Patients Evaluating the Order of Chemotherapy and 
Radiation 
  
  Margin Positive 
  
Post-Op 
Treatment N 
5 Year 
Overall 
Survival (log-
rank p-Value) 
Unadjusted 
Hazard Ratio   
(95% CI) 
Adjusted 
Hazard Ratio 
(95% CI) 
P-Value 
Group 3: 
Stage IIA 
(T1ab-T2a, 
N1) & Stage 
IIB (T3, 
N0;T2b N1) 
No Treatment 419 27 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 284 36 (0.0001) 0.65 (0.53-0.81) 0.72 (0.58-0.9) 0.0041 
Radiation Only 199 26 (0.5907) 1.06 (0.85-1.32) 0.94 (0.74-1.18) 0.5878 
Chemo + Rad 415 37 (<.0001) 0.68 (0.56-0.83) 0.76 (0.62-0.93) 0.0083 
Chemo+Rad 146 37 (0.0106) 0.70 (0.54-0.92) 0.74 (0.56-0.98) 0.034 
Rad+Chemo 120 36 (0.0136) 0.69 (0.52-0.92) 0.76 (0.56-1.02) 0.071 
Chemo=Rad 149 38 (0.0036) 0.66 (0.50-0.87) 0.79 (0.59-1.06) 0.1099 
Group 4: 
Stage IIIA (T1-
3, N2; T3, N1) 
No Treatment 245 12 (Referent) 1.00 (Referent) 1.00 (Referent) 
 
Chemo Only 200 21 (0.0048) 0.70 (0.55-0.90) 0.77 (0.6-1) 0.0466 
Radiation Only 69 10 (0.5215) 1.11 (0.81-1.51) 1.03 (0.74-1.43) 0.8729 
Chemo + Rad 404 25 (<.0001) 0.59 (0.48-0.72) 0.63 (0.51-0.79) <.0001 
Chemo+Rad 173 28 (<.0001) 0.54 (0.42-0.70) 0.56 (0.43-0.74) <.0001 
Rad+Chemo 96 19 (0.0275) 0.70 (0.52-0.95) 0.79 (0.57-1.09) 0.1508 
Chemo=Rad 135 24 (0.0002) 0.58 (0.44-0.77) 0.63 (0.46-0.84) 0.0021 
Supplemental Table VI.   Survival results for Margin Positive Patients by R1, R2, and R-Unknown  
Margin 
Status 
Post-Op 
Treatment 
Stage IIA (T1ab-T2a, N1) & Stage IIB (T3, N0;T2b N1)  Stage IIIA (T1-3, N2; T3, N1)  
Margin Positive (N=1327) Margin Positive (N=919) 
Total 
N 
5 Year Overall 
Survival                        
(log-rank p-
Adjusted Hazard Ratio      
(95% CI) P-Value 
Total 
N 
5 Year 
Overall 
Survival                        
(log-rank 
Adjusted Hazard Ratio     
(95% CI) P-Value 
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value)** p-value)** 
R1 
No Treatment 231 26 (referent) 1.00 (Referent) 
 
127 15 (referent) 1.00 (Referent) 
 
Chemo Only 146 36 (0.0024) 0.65(0.47-0.88) 0.0063 121 19 (0.1362) 0.83(0.59-1.17) 0.2876 
Radiation Only 135 29 (0.5925) 0.83(0.61-1.13) 0.2376 29 13 (0.9215) 0.97(0.57-1.62) 0.8925 
Chemo + Rad 241 37 (0.0019) 0.66(0.5-0.87) 0.0036 237 23 (0.001) 0.66(0.48-0.91) 0.0101 
R2 
No Treatment 13 23 (referent) ID* 
 
14 32 (referent) ID* 
 
Chemo Only 12 48 (0.0833) ID* 5 40 (0.9666) ID* 
Radiation Only 6 0 (0.6098) ID* 6 17 (0.5783) ID* 
Chemo + Rad 22 35 (0.1247) ID* 18 9 (06722) ID* 
RX 
No Treatment 178 31 (referent) 1.00 (Referent) 
 
105 8 (referent) 1.00 (Referent) 
 
Chemo Only 129 35 (0.0503) 0.78(0.55-1.11) 0.1703 78 25 (0.0075) 0.6(0.38-0.95) 0.0284 
Radiation Only 61 23 (0.1165) 1.16(0.76-1.76) 0.4983 35 8 (0.7908) 1.13(0.67-1.91) 0.6458 
Chemo + Rad 153 37 (0.0649) 1.1(0.77-1.57) 0.6078 144 30 (<.0001) 0.48(0.33-0.69) <.0001 
 
*ID= Insufficient Data  **P-value from the log-rank test, comparing the entire survival curves. 
 
 
 
 
 
 
 
 
Supplemental Table VII.  Analysis of Stage Group 4, Margin negative patients by pN stage 
(N0/N1 vs. N2)  
 
 
  
    
Stage Group IV:  Stage IIIA (T1-3, N2; T3, N1)  
 
  
Margin Negative Patients Only (R0) 
Post-Op 
Treatment N 
5 Year Overall 
Survival (log-
rank p-value)** 
Unadjusted 
Hazard Ratio 
(95% CI) 
Adjusted 
Hazard 
Ratio  (95% CI) 
Propensity 
Adjusted 
Hazard 
Ratio  (95% CI) pN Stage 
N0,N1 No Treatment 396 27 (Referent) 1.00 (Referent) 1.00 (Referent) 1.00 (Referent) 
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Chemo Only 464 46 (<.0001) 0.46 (0.37-0.57) 0.49 (0.39-0.62) 2.54 (1.30-4.95) 
Radiation Only 35 28 (0.6906) 1.10 (0.71-1.70) 0.94 (0.59-1.48) 1.08 (0.69-1.69) 
Chemo + Rad 137 23 (0.2422) 0.85 (0.65-1.10) 0.89 (0.67-1.18) 0.92 (0.70-1.21) 
Chemo+Rad 74 23 (0.1490) 0.77 (0.54-1.09) 0.85 (0.59-1.21) 0.84 (0.59-1.19) 
Rad+Chemo 36 12 (0.5019) 1.28 (0.79-2.08) 1.28 (0.77-2.13) 1.11 (0.67-1.84) 
Chemo=Rad 27 29 (0.3696) 0.75 (0.47-1.22) 0.73 (0.44-1.23) 0.96 (0.58-1.59) 
N2 
No Treatment 1723 23 (Referent) 1.00 (Referent) 1.00 (Referent) 1.00 (Referent) 
Chemo Only 2056 38 (<.0001) 0.62 (0.56-0.68) 0.65 (0.59-0.71) 0.65 (0.59-0.72) 
Radiation Only 213 15 (0.0620) 1.20 (1-1.44) 1.18 (0.98-1.42) 1.19 (0.99-1.43) 
Chemo + Rad 1722 40 (<.0001) 0.61 (0.56-0.68) 0.67 (0.60-0.74) 0.69 (0.62-0.76) 
Chemo+Rad 1022 43 (<.0001) 0.55 (0.49-0.62) 0.61 (0.54-0.69) 0.61 (0.54-0.69) 
Rad+Chemo 280 36 (0.0002) 0.70 (0.59-0.84) 0.74 (0.61-0.89) 0.74 (0.62-0.90) 
Chemo=Rad 420 34 (<.0001) 0.72 (0.62-0.84) 0.77 (0.66-0.91) 0.77 (0.66-0.91) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table VIII.   Kaplan Meier Survival Analysis and Proportional Hazards Models by 
Stage Group for Margin Negative Patients Evaluating the Order of Chemotherapy and 
Radiation. 
 
  
   Margin Negative 
  
Post-Op Treatment 
 
N 
5 Year 
Overall 
Survival 
(log-rank p-
Value) 
Unadjusted 
Hazard Ratio   
(95% CI) 
Adjusted 
Hazard Ratio 
(95% CI) 
P-
Value 
Group No Treatment  33780 72 (Referent) 1.00 (Referent) 1.00 (Referent) 
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1: Stage 
IA 
(T1ab, 
N0) 
Chemo Only  789 74 (0.2946) 0.92 (0.78-1.08) 1.02 (0.87-1.2) 0.816 
Radiation Only  136 44 (<.0001) 2.89 (2.22-3.73) 2.18 (1.67-2.85) <.0001 
Chemo + Rad  76 40 (<.0001) 3.19 (2.21-4.59) 2.99 (2.07-4.31) <.0001 
  
 
     Group 
2: Stage 
IB  (T2a, 
N0) &                   
Stage 
IIA (T2b, 
N0) 
No Treatment  19281 57 (Referent) 1.00 (Referent) 1.00 (Referent) 
 Chemo Only  4568 68 (<.0001) 0.68 (0.63-0.72) 0.74 (0.69-0.8) <.0001 
Radiation Only  250 38 (<.0001) 1.92 (1.60-2.31) 1.8 (1.49-2.16) <.0001 
Chemo + Rad 
 
215 47 (0.0003) 1.47 (1.19-1.81) 1.41 (1.14-1.74) 0.0016 
  
 
     Group 
3: Stage 
IIA 
(T1ab-
T2a, N1) 
& Stage 
IIB (T3, 
N0;T2b 
N1) 
No Treatment  6101 37 (Referent) 1.00 (Referent) 1.00 (Referent) 
 Chemo Only  5788 53 (<.0001) 0.59 (0.56-0.63) 0.66 (0.62-0.7) <.0001 
Radiation Only  354 28 (<.0001) 1.35 (1.17-1.57) 1.36 (1.18-1.58) <.0001 
Chemo + Rad  895 41 (0.1772) 0.93 (0.84-1.03) 1.04 (0.93-1.16) 0.4811 
Chemo+Rad  431 42 (0.1966) 0.91 (0.78-1.05) 1 (0.86-1.16) 0.978 
Rad+Chemo  224 36 (0.9445) 0.99 (0.82-1.20) 1.13 (0.93-1.37) 0.209 
Chemo=Rad 
 
240 42 (0.3621) 0.91 (0.75-1.11) 1.03 (0.84-1.26) 0.782 
  
 
     Group 
4: Stage 
IIIA (T1-
3, N2; 
T3, N1) 
No Treatment  2119 24 (Referent) 1.00 (Referent) 1.00 (Referent) 
 Chemo Only  2520 39 (<.0001) 0.59 (0.55-0.65) 0.63 (0.58-0.69) <.0001 
Radiation Only  248 18 (0.0747) 1.18 (0.99-1.39) 1.15 (0.97-1.37) 0.1025 
Chemo + Rad  1859 39 (<.0001) 0.62 (0.57-0.68) 0.69 (0.63-0.76) <.0001 
Chemo+Rad  1096 42 (<.0001) 0.56 (0.50-0.62) 0.62 (0.56-0.7) <.0001 
Rad+Chemo  316 34 (0.0006) 0.74 (0.62-0.87) 0.79 (0.66-0.94) 0.0064 
  Chemo=Rad  447 34 (<.0001) 0.72 (0.62-0.83) 0.77 (0.67-0.9) 0.0006 
 
 
 
 
 
 
Supplemental Table IX. Analysis including only Anatomic Resections 
 
  
  Margin Positive 
  
Post-Op Treatment N Adjusted Hazard Ratio (95% CI) P-Value 
Group 1: Stage IA 
(T1ab, N0) 
No Treatment 197 1.00 (Referent) 
 Chemo Only 13 0.86 (0.18-4.16) 0.8501 
Radiation Only 31 4.14 (1.88-9.09) 0.0004 
Chemo + Rad 14 1.14 (0.38-3.44) 0.8125 
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Group 2: Stage IB 
  (T2a, N0) &                   
Stage IIA (T2b, N0) 
No Treatment 423 1.00 (Referent) 
 Chemo Only 131 0.54 (0.37-0.80) 0.0023 
Radiation Only 100 1.33 (0.96-1.85) 0.0899 
Chemo + Rad 108 0.94 (0.66-1.32) 0.7036 
     Group 3: Stage IIA 
(T1ab-T2a, N1) & Stage 
IIB (T3, N0;T2b N1) 
No Treatment 386 1.00 (Referent) 
 Chemo Only 266 0.75 (0.60-0.95) 0.016 
Radiation Only 177 0.99 (0.77-1.27) 0.9379 
Chemo + Rad 379 0.80 (0.64-0.99) 0.0389 
     
Group 4: Stage IIIA 
 (T1-3, N2; T3, N1) 
No Treatment 220 1.00 (Referent) 
 Chemo Only 179 0.73 (0.56-0.96) 0.0229 
Radiation Only 61 1.05 (0.74-1.48) 0.7959 
Chemo + Rad 356 0.66 (0.53-0.84) 0.0006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table X.  Numbers of Events in Each Analysis Group 
  
  Margin Positive 
 
Margin Negative 
  Post-Op Treatment N Event=death 
 
N Event=death 
Group 1: Stage IA 
(T1ab, N0) 
No Treatment 265 75 (28.3) 
 
33780 5695 (16.86) 
Chemo Only 19 6 (31.58) 
 
789 157 (19.9) 
Radiation Only 60 25 (41.67) 
 
136 55 (40.44) 
Chemo + Rad 25 12 (48)   76 29 (28.16) 
       Group 2: Stage IB  
(T2a, N0) &                   
Stage IIA (T2b, N0) 
No Treatment 477 182 (38.16) 
 
19281 5427 (28.15) 
Chemo Only 142 39 (27.46) 
 
4568 996 (21.8) 
Radiation Only 119 62 (52.1) 
 
250 114 (45.6) 
Chemo + Rad 119 53 (44.54)   215 88 (40.93) 
       Group 3: Stage IIA No Treatment 419 239 (57.04) 
 
6101 2663 (43.65) 
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(T1ab-T2a, N1) & 
Stage IIB (T3, N0;T2b 
N1) 
Chemo Only 284 129 (45.42) 
 
5788 1691 (29.22) 
Radiation Only 199 121 (60.8) 
 
354 198 (55.93) 
Chemo + Rad 415 186 (44.82) 
 
895 398 (44.47) 
Chemo+Rad 146 69 (47.26) 
 
431 186 (43.16) 
Rad+Chemo 120 56 (46.67) 
 
224 109 (48.66) 
Chemo=Rad 149 61 (40.94)   240 103 (42.92) 
       
Group 4: Stage IIIA 
(T1-3, N2; T3, N1) 
No Treatment 245 170 (69.39) 
 
2119 1218 (57.48) 
Chemo Only 200 107 (53.5) 
 
2520 969 (38.45) 
Radiation Only 69 53 (76.81) 
 
248 151 (60.89) 
Chemo + Rad 404 213 (52.72) 
 
1859 791 (42.55) 
Chemo+Rad 173 90 (52.02) 1096 426 (38.87) 
Rad+Chemo 96 54 (56.25) 316 150 (47.47) 
  Chemo=Rad 135 69 (51.11)   447 215 (48.1) 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure I.  Consort Diagram for Margin Negative 
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Figure S-II.  Kaplan Meier Survival Curves for Margin Negative Patients by Stage Group 
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IIA. Group 1 
 
 
 
 
 
 
 
 
 
 
 
IIB. Group 2 
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IIC. Group 3 
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IID. Group 4 
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